A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy Volunteers.

Trial Profile

A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs ATL 1102 (Primary) ; Granulocyte colony-stimulating factors
  • Indications Stem cell mobilisation
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 23 Jul 2014 Results published in the Media Release.
    • 23 Jul 2014 Status changed from recruiting to completed.
    • 27 Mar 2014 New source identified and integrated (Australian & NZ Clinical Trials Register; ACTRN12614000200684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top